Novel oral anticoagulants for stroke prevention in the geriatric population

Daniel Kim, Richard Barna, Mary Barna Bridgeman, Luigi Brunetti

Research output: Contribution to journalReview article

Abstract

Prior to the availability of several newer anticoagulant medications, there had been no new advances in anticoagulation management for stroke prevention since the advent of warfarin in the 1950s. The availability of the novel oral anticoagulants (NOACs) dabigatran, rivaroxaban, and apixaban represent improvements over warfarin in many respects, including the elimination of the need for therapeutic drug monitoring, fewer drug and food interactions, and favorable efficacy; however, these agents are not without risk. Specifically, the use of the NOACs in the geriatric population, who are more likely to have an increased risk of stroke due to atrial fibrillation and other medical comorbidities, is not without risk. The objective of this review is to update the clinician on the use of the NOACs in the geriatric population and introduce the controversies and risks surrounding these newer therapies.

Original languageEnglish (US)
Pages (from-to)15-29
Number of pages15
JournalAmerican Journal of Cardiovascular Drugs
Volume14
Issue number1
DOIs
StatePublished - Feb 2014
Externally publishedYes

Fingerprint

Geriatrics
Anticoagulants
Stroke
Warfarin
Population
Food-Drug Interactions
Drug Monitoring
Atrial Fibrillation
Comorbidity
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Cardiology and Cardiovascular Medicine

Cite this

Novel oral anticoagulants for stroke prevention in the geriatric population. / Kim, Daniel; Barna, Richard; Bridgeman, Mary Barna; Brunetti, Luigi.

In: American Journal of Cardiovascular Drugs, Vol. 14, No. 1, 02.2014, p. 15-29.

Research output: Contribution to journalReview article

Kim, Daniel ; Barna, Richard ; Bridgeman, Mary Barna ; Brunetti, Luigi. / Novel oral anticoagulants for stroke prevention in the geriatric population. In: American Journal of Cardiovascular Drugs. 2014 ; Vol. 14, No. 1. pp. 15-29.
@article{d0b12a85dc46481e92503b354b8ee5c6,
title = "Novel oral anticoagulants for stroke prevention in the geriatric population",
abstract = "Prior to the availability of several newer anticoagulant medications, there had been no new advances in anticoagulation management for stroke prevention since the advent of warfarin in the 1950s. The availability of the novel oral anticoagulants (NOACs) dabigatran, rivaroxaban, and apixaban represent improvements over warfarin in many respects, including the elimination of the need for therapeutic drug monitoring, fewer drug and food interactions, and favorable efficacy; however, these agents are not without risk. Specifically, the use of the NOACs in the geriatric population, who are more likely to have an increased risk of stroke due to atrial fibrillation and other medical comorbidities, is not without risk. The objective of this review is to update the clinician on the use of the NOACs in the geriatric population and introduce the controversies and risks surrounding these newer therapies.",
author = "Daniel Kim and Richard Barna and Bridgeman, {Mary Barna} and Luigi Brunetti",
year = "2014",
month = "2",
doi = "10.1007/s40256-013-0050-3",
language = "English (US)",
volume = "14",
pages = "15--29",
journal = "American Journal of Cardiovascular Drugs",
issn = "1175-3277",
publisher = "Adis International Ltd",
number = "1",

}

TY - JOUR

T1 - Novel oral anticoagulants for stroke prevention in the geriatric population

AU - Kim, Daniel

AU - Barna, Richard

AU - Bridgeman, Mary Barna

AU - Brunetti, Luigi

PY - 2014/2

Y1 - 2014/2

N2 - Prior to the availability of several newer anticoagulant medications, there had been no new advances in anticoagulation management for stroke prevention since the advent of warfarin in the 1950s. The availability of the novel oral anticoagulants (NOACs) dabigatran, rivaroxaban, and apixaban represent improvements over warfarin in many respects, including the elimination of the need for therapeutic drug monitoring, fewer drug and food interactions, and favorable efficacy; however, these agents are not without risk. Specifically, the use of the NOACs in the geriatric population, who are more likely to have an increased risk of stroke due to atrial fibrillation and other medical comorbidities, is not without risk. The objective of this review is to update the clinician on the use of the NOACs in the geriatric population and introduce the controversies and risks surrounding these newer therapies.

AB - Prior to the availability of several newer anticoagulant medications, there had been no new advances in anticoagulation management for stroke prevention since the advent of warfarin in the 1950s. The availability of the novel oral anticoagulants (NOACs) dabigatran, rivaroxaban, and apixaban represent improvements over warfarin in many respects, including the elimination of the need for therapeutic drug monitoring, fewer drug and food interactions, and favorable efficacy; however, these agents are not without risk. Specifically, the use of the NOACs in the geriatric population, who are more likely to have an increased risk of stroke due to atrial fibrillation and other medical comorbidities, is not without risk. The objective of this review is to update the clinician on the use of the NOACs in the geriatric population and introduce the controversies and risks surrounding these newer therapies.

UR - http://www.scopus.com/inward/record.url?scp=84893523494&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893523494&partnerID=8YFLogxK

U2 - 10.1007/s40256-013-0050-3

DO - 10.1007/s40256-013-0050-3

M3 - Review article

VL - 14

SP - 15

EP - 29

JO - American Journal of Cardiovascular Drugs

JF - American Journal of Cardiovascular Drugs

SN - 1175-3277

IS - 1

ER -